Zubida Al-Majdoub, currently a Research Fellow at the Division of Pharmacy and Optometry, University of Manchester, holds a Ph.D. from the Manchester Institute of Biotechnology and the School of Pharmacy and Pharmaceutical Sciences.The QconCAT technology is now world leading in the field of Quantitative ADME to support mechanistic modelling and simulation. Zubida work has been expanded towards liquid biopsy approach by isolating exosomes from plasma and cerebrospinal fluid (CSF) to monitor expression of ADME proteins and inter-individual variability With expertise in quantitative proteomics and transcriptomics, Zubida’s research focuses on pharmaco-‘omics’, particularly in drug metabolism and drug transport pathways. Her pioneering work in applying QconCAT technology to study ADME proteins has made significant contributions to the field. Zubida is also actively involved in supervising PhD and MPhil students, providing guidance in research projects and laboratory skills development. Additionally, she has served as an examiner for both internal and external PhD assessments, demonstrating her commitment to academic excellence and mentorship in the field of pharmacokinetic research.
Professional Profile:
Scopus
Orcid
📚Education :
Zubida Al-Majdoub holds a Ph.D. in Quantification of Ribosomal Proteins by Mass Spectrometry: An Approach to Drug Target Identification, earned from the Manchester Institute of Biotechnology (MIB) and School of Pharmacy and Pharmaceutical Sciences at the University of Manchester, UK, spanning from 2008 to 2013. Prior to her doctoral studies, she completed an MPhil in Design and Synthesis of Pro-drugs of Erythromycin A at the same institution from 2003 to 2006. Zubida began her academic journey by obtaining a B. Pharm from the School of Pharmacy at Tripoli University of Medical Sciences in Tripoli, Libya, graduating in 1995. These educational accomplishments reflect her commitment to advancing knowledge and expertise in pharmaceutical sciences.
💼Work Experience:
Zubida Al-Majdoub’s dedication to nurturing the next generation of researchers is evident in her role as a mentor during work experience placements. She provided guidance and support to college and high school students, offering them valuable insights into proteomic data analysis and microbiological proteomics. Through these mentoring experiences, Zubida has played a vital role in shaping the development of aspiring researchers, showcasing her commitment to fostering talent in the scientific community.
🔬Research Contributions:
Zubida Al-Majdoub’s research focuses on pharmaco-‘omics’ with expertise in quantitative proteomics and transcriptomics for pharmacologically-relevant pathways involved in drug metabolism and transport. Her work contributed significantly to the application of QconCAT technology in studying ADME (absorption, distribution, metabolism, and excretion) proteins, now a world-leading approach in Quantitative ADME. Currently, she expands her research towards liquid biopsy approaches for monitoring ADME proteins and inter-individual variability.
Publication Top Notes:
1.”Complementarity of two proteomic data analysis tools in the identification of drug-metabolising enzymes and transporters in human liver” in Molecular Omics, 2023, cited by no articles.
2.”Proteomic quantification of receptor tyrosine kinases involved in the development and progression of colorectal cancer liver metastasis” in Frontiers in Oncology, 2023, cited by no articles.
3.”Quantitative Assessment of the Impact of Crohn’s Disease on Protein Abundance of Human Intestinal Drug-Metabolising Enzymes and Transporters” in Journal of Pharmaceutical Sciences, 2022, cited by 2 articles.
4.”Quantitative Proteomics of Hepatic Drug-Metabolizing Enzymes and Transporters in Patients With Colorectal Cancer Metastasis” in Clinical Pharmacology and Therapeutics, 2022, cited by 6 articles.